Annual report pursuant to Section 13 and 15(d)

Note 3 - Revenue From Contracts With Customers (Tables)

v3.23.1
Note 3 - Revenue From Contracts With Customers (Tables)
12 Months Ended
Dec. 31, 2022
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Years Ended

December 31,

 
   

2022

   

2021

 
Sales revenue:                

Tc99m tilmanocept – Europe

  $ 14,035     $  

Tc99m tilmanocept – Australia

    610        

Total sales revenue

    14,645        
                 

License revenue:

               

Tc99m tilmanocept - Europe

  $     $ 45,615  
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
   

Years Ended December 31,

 
   

2022

   

2021

 

Total deferred revenue related to contracts with customers, beginning of period

  $ 700,000     $ 700,000  

Deferred revenue related to milestones achieved

    100,000        

Deferred revenue related to milestones achieved, written off due to contract renegotiations

    (100,000 )      

Total deferred revenue related to contracts with customers, end of period

  $ 700,000     $ 700,000